Πλοήγηση ανά Θέμα "immunologic factor"
Αποτελέσματα 1-7 από 7
-
Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment
(2019)Background: Development of autoimmune hepatitis (AIH) has been sporadically reported in patients with multiple sclerosis (MS) either concurrently or after treatment with immunomodulatory drugs, including interferon-beta ... -
IFNs-signaling effects on lung cancer: an up-to-date pathways-specific review
(2017)IFNs have found important applications in clinical medicine, including the treatment of lung malignancies. The biological effect of the IFN-receptor signaling is regulated essentially by three factors: the expression profile ... -
IL-35: a new immunomodulator in autoimmune rheumatic diseases
(2018)IL-35 is a relatively new cytokine that emerges as an important immunomodulator. IL-35 belongs to IL-12 cytokine family that includes IL-12, IL-23, IL-27, and IL-35. These cytokines are heterodimers that share subunits and ... -
Long-Term Effectiveness of Natalizumab in Patients with Relapsing-Remitting Multiple Sclerosis Treated in the Routine Care in Greece: Results from the Multicenter, Observational 5-Year Prospective Study ‘TOPICS Greece’
(2021)Background and Objectives: For chronic diseases like multiple sclerosis (MS), real-world evidence on long-term treatment outcomes is essential. The study aimed to provide long-term data on the safety and effectiveness of ... -
On the immunoregulatory role of statins in multiple sclerosis: the effects on Th17 cells
(2019)Statins, the cholesterol-lowering drugs, also possess immunomodulatory properties, affecting among others T cell activation and differentiation, antigen presentation, and regulatory T cell (Tregs) maintenance and ... -
Phosphodiesterase 4 inhibitors in immune-mediated diseases: Mode of action, clinical applications, current and future perspectives
(2017)Phosphodiesterase (PDE) 4 is a superfamily of enzymes that catalyze the hydrolysis of cyclic adenosine 3', 5'-monophosphate (cAMP), an intracellular second messenger and regulator of a wide array of genes and proteins. ... -
Targeting very early systemic sclerosis: a case-based review
(2019)It is unknown whether treatment in very early/early systemic sclerosis (SSc) can affect long-term outcomes. A case-based review was conducted (i) to assess the effect of rituximab (RTX) in very early SSc and (ii) to explore ...